We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOptiBiotix Health Regulatory News (OPTI)

Share Price Information for OptiBiotix Health (OPTI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.00
Bid: 17.50
Ask: 18.50
Change: 0.75 (4.35%)
Spread: 1.00 (5.714%)
Open: 17.75
High: 18.00
Low: 17.75
Prev. Close: 17.25
OPTI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Commercial Appointments

1 Mar 2022 07:00

RNS Number : 0988D
OptiBiotix Health PLC
01 March 2022
 

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Commercial Appointments

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, blood pressure, diabetes, announces the following appointments1: Zac Sniderman as Business Development & Sales Director North America, Shiraz Butt as E-Commerce Director and Karl Burkitt as Marketing Director.

 

Zac brings a broad experience developing a food and supplement ingredient businesses in North America working for Galenicum Speciality Ingredients, Jarrow Formulas and Best Ground International. He has an entrepreneurial mindset and an extensive network. He will focus on the development of ingredient sales to brand owners and contract manufacturers for both pro- and prebiotics in close cooperation with our established partners.

 

Shiraz has successfully developed the e-commerce businesses for a range of companies, such as PhD (now part of Science In Sports) and Iovate Health Sciences. He has built digital sales from the ground up into significant contributors to the success of the companies he has worked for. Shiraz will focus on developing the untapped e-commerce potential of our pro- and prebiotic brands such as SlimBiome Medical, Go-Figure and CholBiome.

 

Karl Burkitt has a rich career in which he developed and led the marketing and business development function in various branded and ingredient businesses, such as Novartis Consumer Health, Kerry Ingredients & Flavours and AB Mauri. Karl will lead our marketing function, on a part time basis, and work closely with the pro- and prebiotic commercial divisions on developing ingredient and consumer sales.

 

The above appointments expand the capabilities of our management team in line with our commercial strategy, which is to further expand ingredient sales, particularly in the large North American market, whilst developing our final product sales containing our unique ingredients.

 

René Kamminga, CEO of OptiBiotix Ltd, commented: "In the past 12 months we have established the credibility and brand awareness of our science-based ingredients SlimBiome®, OptiBiome, LeanBiome and LPLDL® ingredients, significantly growing sales to a wider number of reputable global brands in multiple markets. These appointments are a further investment to accelerate the growth of the Company and to broaden and deepen our income streams with a particular focus on North America and E-Commerce."

 

1These appointments are non-statutory director appointments in the Company or its subsidiaries.

 

For further information, please contact:

 

OptiBiotix Health plc

www.optibiotix.com

Stephen O'Hara, Chief Executive

Contact via Walbrook below

 

 

 

 

Cenkos Securities plc (Broker)

Tel: 020 7397 8900

Callum Davidson / Neil McDonald

 

Michael Johnson / Russell Kerr (Sales)

 

 

 

Walbrook PR Ltd

Mob: 07407 804 654

Alice Woodings

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained in this announcement is of a non-regulatory nature. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRATPMRTMTJTBAT
Date   Source Headline
18th Nov 20207:00 amRNSLicense and supply agreement with Genuine Health
12th Oct 20207:00 amRNSLaunch of weight management products
9th Oct 20202:00 pmRNSInvestor presentation
8th Oct 20207:00 amRNSHead of Quality & Operations appointment
6th Oct 20207:00 amRNSExclusive distribution agreement
5th Oct 202011:05 amRNSSecond Price Monitoring Extn
5th Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 202011:00 amRNSPrice Monitoring Extension
2nd Oct 20207:00 amRNSFDA Investigational New Drug authorisation
28th Sep 20207:00 amRNSExclusive distribution agreement
24th Sep 20207:00 amRNSHalf-year Report
22nd Sep 20207:00 amRNSLicense agreement for SlimBiome® Medical in the US
17th Sep 20207:00 amRNSDistributor agreement with Ayalla Marketing
15th Sep 202011:06 amRNSSecond Price Monitoring Extn
15th Sep 202011:00 amRNSPrice Monitoring Extension
15th Sep 20207:00 amRNSSweetBiotix sweet fibres agreement
3rd Sep 20202:05 pmRNSSecond Price Monitoring Extn
3rd Sep 20202:00 pmRNSPrice Monitoring Extension
3rd Sep 202011:05 amRNSSecond Price Monitoring Extn
3rd Sep 202011:00 amRNSPrice Monitoring Extension
11th Aug 20207:00 amRNSScientific and commercial development update
5th Aug 20207:00 amRNSExtension of terms for OptiBiome with OptiPharm
30th Jul 20207:00 amRNSExtension of terms for WellBiome with Maxum Foods
23rd Jul 20207:00 amRNSExtension of terms for WellBiome with Agropur
20th Jul 20207:00 amRNSTrading and commercial update
16th Jul 20207:00 amRNSExtension of terms, territories and products
14th Jul 20207:00 amRNSExtension of terms for WellBiome
9th Jul 202011:29 amRNSResult of AGM
6th Jul 20207:00 amRNSExtension of terms for WellBiome
1st Jul 20207:00 amRNSDistribution agreement with Actial Farmaceutica
29th Jun 20207:00 amRNSLaunch of WellBiome
17th Jun 20207:00 amRNSNotice of AGM
3rd Jun 20207:00 amRNSExercise of Warrant
2nd Jun 20203:35 pmRNSGrant of Options
1st Jun 20203:45 pmRNSHolding(s) in Company
1st Jun 20207:00 amRNSCambridge Commodities appointment as distributor
28th May 20207:00 amRNSFinal Results
20th May 20207:00 amRNSLaunch of SlimBiome gummies in USA
18th May 20207:00 amRNSTrading and commercial update
11th May 20207:00 amRNSExclusive distribution agreement with MAXCARE Inc
5th May 20207:00 amRNSDistribution of products in China and Hong Kong
4th May 20207:00 amRNSNon-exclusive agreement with Smart For Life
17th Apr 20204:24 pmRNSHolding(s) in Company
17th Apr 202011:03 amRNSPlacing and Related Party Transaction
6th Apr 20207:00 amRNSSlimBiome® contract manufacturing agreement
2nd Apr 20207:00 amRNSSlimBiome® contract manufacturing agreement
31st Mar 20207:00 amRNSExclusive licence agreement for OptiBiome®
24th Mar 20207:00 amRNSExtension of territories for GoFigure®
23rd Mar 20207:00 amRNSChange of accounting year end
19th Mar 20204:42 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.